Our results demonstrate that GLP-1 receptor agonists provide better cardiovascular protection than SGLT2 inhibitors in patients with HFpEF and DM, significantly reducing the risk of cardiovascular events, progression to SHF, and stroke. This evidence concerns the gene GLP1R and stroke disorder.